Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 149-152

  Peres, E ^a,b   Levine, J E ^b   Khaled, Y A ^b   Ibrahim, R B ^a   Braun, T M ^b   Krijanovski, O I ^b   Mineishi, S ^b   Abidi, M H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cardiac complications; Conditioning chemotherapy; RIC

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; BUSULFAN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TROPONIN;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART EJECTION FRACTION; HEART INFARCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODYNAMICS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SUPRAVENTRICULAR TACHYCARDIA; WHOLE BODY RADIATION;

ADULT; AGED; ANTHRACYCLINES; ARRHYTHMIAS, CARDIAC; BUSULFAN; FEMALE; HEART DISEASES; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 75149188185     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.97     Document Type: Article

References (31)

1. Craddock C. Haemopoietic stem cell transplantation: recent progress and future promise. Lancet Oncol 2000; 1: 227-234.
2. Bearman SI, Petersen FB, Schor RA, Denney JD, Fisher LD, Appelbaum FR et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
3. Braverman AC, Antin JH, Plappert MT, Cooke EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
4. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25: 885-894.
5. Fujimaki K, Maruta A, Yoshida M, Sakai R, Tanabe J, Koharazawa H et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307-310.
6. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
7. Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Goller V, Clausen M et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.
8. Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
9. Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute Experience. Br J Cancer 2003; 88: 1831-1838.
10. Slavin S, Nagler A, Naparstek E, Kapelushniky Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
11. Appelbaum F, Strauchen JA, Graw RG, Savage DD, Kent KM, Ferrans VJ et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
12. Mullins GM, Anderson PN, Antos GW. High-dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic and immunosuppressive effects. Cancer 1975; 36: 1950-1958.
13. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature. Cancer 1979; 43: 2223-2226.
14. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
15. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
16. Olivieri A, Corvatta L, Montanari M, Brunori M, Offidani M, Ferretti GF et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998; 21: 1049-1053.
17. Moreau P, Milpied N, Mahe B, Juge-Marineau N, Rapp MJ, Bataille R et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003-1006.
18. Steinherz LJ, Steinherz PG, Mangiacasale D, O'Reilly R, Allen J, Sorell M et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981; 9: 417-422.
19. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819-829. (Pubitemid 34752678)
20. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 2000; 6: 198-203.
21. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
22. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M et al. Regimen-related toxicity after fludarabinemelphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32: 471-476. (Pubitemid 37160961)
23. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urvano-Ispizua A et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659. (Pubitemid 34015658)
24. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity: characterising and avoiding the problem. Drugs 1991; 42: 781-795.
25. Phillips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004; 10: 473-483.
26. Spriano M, Clavio M, Carrara P, Canepa L, Miglino M, Pierri I et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica 1994; 79: 218-224.
27. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101-103.
28. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
29. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262.
30. Armenian SH, Sun CL, Francisco L, Steinberger J, Kurian S, Wong FL et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008; 26: 5537-5543.
31. Fazio S, Palmieri EA, Ferravante B, Bone F, Biondi B, Facca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 1998; 21: 777-779.